A Deep-Dive Comparison for Clinical Trials and Regulatory Data Science
For statistical programmers working in clinical trials, the analytical landscape has historically centered on SAS. That dominance is now being challenged by two open-source ecosystems—Python and R—each bringing distinct strengths to the clinical data pipeline. As regulatory agencies including the FDA and PMDA increasingly accept open-source submissions, the practical question is no longer whether to adopt these languages, but when and how to deploy each one effectively.
This article provides a practitioner-level comparison of Python and R, examined through the lens of what statistical programmers actually do: build SDTM and ADaM datasets, produce Tables, Figures, and Listings (TFLs), validate outputs, and prepare regulatory submission packages. The goal is not to declare a winner, but to map the similarities, differences, and complementary strengths that inform real-world tool selection.
R was created in 1993 by Ross Ihaka and Robert Gentleman at the University of Auckland as an open-source implementation of the S language. Its DNA is statistical: R was designed by statisticians, for statisticians. The language's core data structure—the data frame—maps directly to the rectangular datasets that statistical programmers work with every day. R's formula syntax (y ~ x1 + x2), factor handling, and built-in statistical distributions reflect a language that treats statistical modeling as a first-class operation.
Python was created in 1991 by Guido van Rossum as a general-purpose programming language emphasizing readability and simplicity. Python was not designed for statistics—it was designed for everything. Its data science capabilities emerged later through third-party libraries: NumPy (2005), pandas (2008), and scikit-learn (2010). This general-purpose heritage gives Python advantages in software engineering practices, system integration, and deployment, but means that statistical functionality is always mediated through external packages rather than built into the language core.
This philosophical difference permeates every comparison that follows. R provides domain-native syntax for statistical operations; Python provides a more uniform programming model that extends into statistics through well-engineered libraries.
Both languages are dynamically typed, interpreted, and support interactive REPL-style development. But the syntactic differences are significant enough to affect daily productivity during the learning curve.
| Feature Python R | ||
| Assignment | x = 10 | x <- 10 (or x = 10) |
| Indexing | Zero-based: lst[0] | One-based: vec[1] |
| Pipe operator | Method chaining: df.query().groupby() | ` |
| Function definition | def fn(x): return x + 1 | fn <- function(x) { x + 1 } |
| Package loading | import pandas as pd | library(dplyr) |
| Boolean values | True / False | TRUE / FALSE |
| NULL / missing | None / np.nan | NULL / NA (typed: NA_real_, etc.) |
| String formatting | f"Value: {x}" | paste0("Value: ", x) or glue("{x}") |
| List comprehension | [x**2 for x in range(10)] | sapply(0:9, function(x) x^2) |
| Vectorized ops | Via NumPy: np.array([1,2]) + 1 | Native: c(1,2) + 1 |
Key syntactic similarity: Both languages support vectorized operations on arrays and data frames, which is the fundamental programming paradigm for statistical data manipulation. The difference is that R provides vectorization natively, while Python achieves it through NumPy and pandas. For a SAS programmer transitioning to either language, the core mental model of applying operations across rows and columns transfers directly.
Key syntactic difference: R's one-based indexing aligns with SAS (where arrays and observations start at 1), while Python's zero-based indexing follows the C/Java convention. This is a persistent source of off-by-one errors during transition and is worth deliberate attention during onboarding.
Both languages center their data science workflows on the data frame—a two-dimensional, labeled, column-oriented structure that maps directly to SAS datasets and CDISC domain structures. In R, the data.frame is a built-in type. In Python, pandas.DataFrame provides equivalent functionality. Both support mixed column types, named columns, row selection, column derivation, and merge/join operations.
| Operation Python (pandas) R (dplyr / base) | ||
| Read SAS dataset | pd.read_sas("dm.sas7bdat") | haven::read_sas("dm.sas7bdat") |
| Filter rows | df[df["AGE"] > 65] | filter(df, AGE > 65) |
| Select columns | df[["SUBJID","AGE"]] | select(df, SUBJID, AGE) |
| Create variable | df["AGEGR"] = np.where(df["AGE"]>=65,">=65","<65") | df <- mutate(df, AGEGR = if_else(AGE >= 65, ">=65", "<65")) |
| Sort | df.sort_values(["SITEID","SUBJID"]) | arrange(df, SITEID, SUBJID) |
| Group & summarize | df.groupby("TRT").agg(N=("SUBJID","nunique")) | df |> group_by(TRT) |> summarise(N = n_distinct(SUBJID)) |
| Merge (left join) | pd.merge(adsl, adae, on="USUBJID", how="left") | left_join(adsl, adae, by = "USUBJID") |
| Transpose | df.T or df.pivot_table() | t(df) or pivot_wider() |
| Write to XPT | pyreadstat.write_xport(df, "dm.xpt") | haven::write_xpt(df, "dm.xpt") |
Clinical datasets require precise handling of dates, categorical variables (e.g., AESEV, RACE), and controlled terminology. R has a native advantage here: factor types directly model categorical variables with ordered levels, and R's Date and POSIXct classes handle ISO 8601 date/datetime formats used in SDTM (--DTC variables). Python's pandas.Categorical and pd.to_datetime() provide equivalent functionality, but require explicit invocation rather than being the default behavior.
For SAS format-style value labeling (e.g., 1 = "Male", 2 = "Female" for SEX), R's haven package preserves SAS format metadata on import. Python's pyreadstat can read these labels but does not natively attach them to the DataFrame in the same transparent way.
R's statistical heritage makes it the more expressive language for classical inference. Base R includes functions for t-tests, chi-squared tests, ANOVA, linear and logistic regression, survival analysis, and nonparametric methods—all without installing additional packages. Python achieves comparable coverage through SciPy, statsmodels, and scikit-learn, but requires assembling these pieces explicitly.
| Analysis SAS Procedure R Python | |||
| Linear regression | PROC REG / PROC GLM | lm(y ~ x, data) | statsmodels.OLS(y, X).fit() |
| Logistic regression | PROC LOGISTIC | glm(y ~ x, family=binomial) | statsmodels.Logit(y, X).fit() |
| Survival (KM) | PROC LIFETEST | survival::survfit(Surv(t,e) ~ grp) | lifelines.KaplanMeierFitter() |
| Cox PH model | PROC PHREG | survival::coxph(Surv(t,e) ~ x) | lifelines.CoxPHFitter() |
| Mixed models | PROC MIXED | lme4::lmer(y ~ x + (1|subj)) | statsmodels.MixedLM() |
| ANOVA / ANCOVA | PROC GLM | aov() / car::Anova() | statsmodels.anova_lm() |
| CMH test | PROC FREQ (CMH option) | vcdExtra::CMHtest() / stats::mantelhaen.test() | scipy + manual implementation |
| MMRM | PROC MIXED (REPEATED) | mmrm::mmrm() | Limited (statsmodels or custom) |
Regulatory note: For analyses requiring numerical reproducibility with SAS outputs—particularly MMRM, ANCOVA, and CMH tests that appear in primary efficacy tables—R currently has stronger parity. The mmrm R package, developed under the pharmaverse initiative, was specifically designed to match PROC MIXED REPEATED statement results. Python lacks an equivalent validated, purpose-built clinical MMRM implementation as of this writing.
Python holds a decisive advantage in machine learning and deep learning. scikit-learn provides a unified API for classification, regression, clustering, and dimensionality reduction. TensorFlow and PyTorch dominate deep learning. For clinical applications such as biomarker discovery, imaging endpoints, and real-world evidence (RWE) analytics, Python's ML ecosystem is substantially more mature.
R has capable ML tools (caret, tidymodels, xgboost), but the ecosystem is smaller and less actively developed for deep learning. R's strengths lie in statistical learning methods (GAMs, Bayesian models via brms/Stan) rather than production ML pipelines.
The most significant development in R's clinical positioning is the pharmaverse (pharmaverse.org)—a curated collection of R packages purpose-built for clinical trial data workflows. Key packages include:
| Package Function SAS Equivalent Context | ||
| {admiral} | ADaM dataset construction with modular derivation functions | ADaM programming logic |
| {sdtm.oak} | SDTM mapping from raw/operational data using declarative syntax | SDTM mapping specs |
| {teal} | Interactive Shiny-based clinical data exploration and TFL review | JMP Clinical / ad hoc review |
| {rtables} | Regulatory-grade table construction with cell formatting | PROC REPORT / TFL shells |
| {tern} | Statistical analysis functions for common clinical endpoints | Macro libraries |
| {mmrm} | Mixed Models for Repeated Measures with SAS-validated results | PROC MIXED (REPEATED) |
| {chevron} | Standardized TFL templates using rtables + tern | Standard TFL macros |
| {riskassessment} | R package validation and risk scoring per R Validation Hub framework | IQ/OQ validation |
This ecosystem represents a coordinated industry effort—backed by Roche, GSK, Janssen, and other sponsors—to make R a first-class language for regulatory submissions. The pharmaverse packages are designed to produce outputs that match SAS-generated results, addressing the key regulatory concern around numerical consistency.
Python's clinical trials ecosystem is less mature and more fragmented than R's pharmaverse. Key packages and efforts include:
| Package / Project Function Maturity | ||
| pyreadstat | Read/write SAS7BDAT, XPT, SPSS, Stata files | Stable |
| pandas | Data manipulation (ADaM/SDTM construction) | Stable (general-purpose) |
| statsmodels | Statistical modeling (regression, ANOVA, survival) | Stable (general-purpose) |
| lifelines | Survival analysis (KM, Cox PH) | Stable |
| tableone | Baseline characteristics tables (Table 1) | Moderate |
| PHUSE open-source projects | Community scripts for clinical standards | Emerging |
| Transcelerate / CDISC | Exploring Python for USDM and automation tools | Early |
Python does not yet have a coordinated, industry-backed equivalent to the pharmaverse. Individual packages serve specific needs well, but there is no unified framework connecting SDTM creation, ADaM derivation, TFL generation, and define.xml production in a single Pythonic pipeline. This gap is the single largest barrier to Python adoption for end-to-end regulatory submission programming.
R's ggplot2 is widely regarded as the gold standard for statistical graphics. Its grammar-of-graphics approach maps statistical variables to visual aesthetics in a declarative, layered syntax. For clinical trial figures—Kaplan-Meier curves, forest plots, waterfall plots, swimmer plots—the combination of ggplot2 with clinical-specific extensions (ggsurvfit, visR, forester) provides publication-ready output with minimal customization.
Python's matplotlib offers more granular control but requires more code for equivalent output. seaborn adds statistical visualization layers on top of matplotlib. plotly excels at interactive visualizations. For clinical figures, Python typically requires more manual construction, though plotnine (a ggplot2 port) can reduce this gap.
Interactive dashboards: R's Shiny framework is more established in clinical settings, with pharmaverse's {teal} providing clinical-specific modules. Python's Streamlit and Dash offer comparable functionality and are gaining traction for RWE and internal analytics.
This is the dimension that matters most for statistical programmers preparing regulatory submissions. The landscape is evolving rapidly.
The FDA has accepted R-based submissions since the Roche pilot 1 submission in 2021 and has since received multiple R-inclusive packages. The agency's position, reiterated through CDER communications, is technology-agnostic: the FDA evaluates the integrity and reproducibility of submitted analyses, not the software used to produce them. The Japan PMDA has similarly indicated openness to open-source tooling.
Python-based submissions are technically permissible under the same framework, but fewer precedents exist. The practical challenge is not regulatory prohibition but industry readiness: validated package ecosystems, reproducibility infrastructure, and reviewer familiarity.
The R Validation Hub (pharmar.org) has established a risk-based framework for assessing R package reliability, producing the {riskmetric} and {riskassessment} packages. This framework evaluates packages on test coverage, documentation quality, maintenance activity, and community adoption—providing a structured alternative to traditional IQ/OQ/PQ validation.
Python lacks an equivalent industry-coordinated validation framework. Organizations adopting Python for clinical work typically develop internal qualification protocols, which increases the barrier to adoption compared to R's community-supported approach.
Both languages support reproducible environments, but with different tooling. R uses renv for package version locking (analogous to a SAS installation snapshot). Python uses pip freeze / requirements.txt or conda environments. Both can be containerized via Docker for full environment reproducibility. For regulatory submissions, the critical requirement is that an independent reviewer can reconstruct the analysis environment and reproduce results—both languages can achieve this with proper discipline.
For typical clinical trial datasets (10,000–100,000 subjects, dozens of domains), both Python and R perform adequately. Performance differences become meaningful at scale:
| Dimension Python R | ||
| Large dataset handling | pandas handles millions of rows; Polars and Dask for out-of-core processing | data.table excels at in-memory speed; arrow package for larger-than-RAM data |
| Computation speed | NumPy's C backend is fast; Cython/Numba for optimization | Vectorized R is fast; Rcpp for C++ integration when needed |
| Parallel processing | multiprocessing, concurrent.futures, joblib | parallel, future, furrr packages |
| Cloud/HPC integration | Native fit with AWS, GCP, Azure SDKs | Growing support via cloud.R packages; Posit Connect for deployment |
| Memory efficiency | More predictable memory model; explicit dtype control | Copy-on-modify semantics can cause unexpected memory spikes |
Clinical relevance: For RWE studies involving claims databases or EHR extracts with millions of records, Python's scalability ecosystem (Polars, Dask, PySpark) is more mature. For standard clinical trial datasets, performance is a non-differentiator.
Most statistical programming groups will not abandon SAS overnight. The practical question is how well Python and R interoperate with existing SAS infrastructure.
| Integration Point Python R | ||
| Read SAS7BDAT | pyreadstat (preserves formats/labels) | haven::read_sas() (preserves formats/labels) |
| Write XPT v5 | pyreadstat.write_xport() | haven::write_xpt() (v5 compliant) |
| Call SAS from code | SASPy (requires SAS license) | SASmarkdown / sasr (requires SAS license) |
| Call code from SAS | PROC PYTHON (SAS Viya) | PROC IML + R interface |
| Numerical matching | Requires careful float handling | pharmaverse packages designed for SAS parity |
| define.xml production | Limited tooling; manual XML construction | Emerging: defineR, metacore packages |
For organizations in transition, a common pattern is to use SAS for primary efficacy analyses (where numerical matching is critical for reviewer comfort), R for exploratory analyses and select TFLs, and Python for data engineering, ML-based endpoints, and automation infrastructure. This polyglot approach leverages each language's strengths while managing regulatory risk.
R: RStudio (now Posit) is the dominant IDE. It provides integrated console, script editor, environment viewer, help system, and package management in a single interface purpose-built for statistical workflows. Posit Workbench extends this to enterprise multi-user server environments. R Markdown and Quarto enable literate programming that combines code, output, and narrative—ideal for statistical analysis reports.
Python: The ecosystem offers more IDE choices: VS Code (with Python/Jupyter extensions), PyCharm, JupyterLab, and Positron (Posit's new multi-language IDE). Jupyter Notebooks provide a similar literate programming experience to R Markdown. VS Code's flexibility makes it particularly strong for projects that span Python, R, and shell scripting.
Shared ground: Both languages support version control via Git, CI/CD pipelines (GitHub Actions, GitLab CI), and containerized deployment. Quarto, developed by Posit, now supports both R and Python as first-class languages, enabling bilingual reports from a single document.
The transition path from SAS differs meaningfully between the two languages.
SAS to R: The conceptual distance is shorter. R's data frame maps to a SAS dataset. R's one-based indexing matches SAS arrays. PROC-style operations translate naturally to dplyr verbs (filter = WHERE, mutate = assignment, summarise = PROC MEANS). R's formula interface (y ~ trt + baseline) maps to SAS MODEL statements. The pharmaverse provides clinical-specific functions that a SAS programmer can recognize conceptually. Typical ramp-up to productive ADaM programming: 2–4 months.
SAS to Python: The conceptual distance is greater. Python's zero-based indexing, object-oriented paradigm, and general-purpose syntax require more adjustment. pandas' method-chaining style is powerful but unfamiliar. However, Python's syntax is cleaner and more consistent, and programmers who invest in the learning curve often report that Python's general programming capabilities (file I/O, API calls, text processing, automation) open up workflow possibilities that were cumbersome in SAS. Typical ramp-up to productive data manipulation: 3–6 months.
Rather than prescribing one language, the following framework maps use cases to language strengths based on the current state of the clinical ecosystem.
| Use Case Recommended Rationale | ||
| Primary efficacy TFLs for regulatory submission | R (or SAS) | pharmaverse provides validated, SAS-parity packages; stronger regulatory precedent |
| Exploratory data analysis & visualization | R | ggplot2 + Shiny + teal provide unmatched statistical visualization |
| ADaM dataset construction | R | {admiral} provides modular, documented derivation framework |
| SDTM mapping from raw data | R | {sdtm.oak} offers declarative mapping syntax with CDISC alignment |
| Machine learning endpoints (biomarkers, imaging) | Python | scikit-learn, TensorFlow, PyTorch ecosystem is substantially deeper |
| Data engineering & pipeline automation | Python | Native cloud SDK integration, REST APIs, file manipulation |
| RWE / large-scale observational studies | Python | Polars/Dask/PySpark handle scale; broader NLP tooling for unstructured data |
| Interactive clinical dashboards | R (Shiny) or Python (Streamlit) | Both capable; Shiny more established in pharma; Streamlit faster to prototype |
| define.xml and submission metadata | R (emerging) | metacore/defineR packages; Python tooling still limited |
| Cross-functional collaboration (DS/Engineering) | Python | Shared language with data engineering, MLOps, and software teams |
Several trends are narrowing the gap between Python and R in clinical settings:
Posit's bilingual strategy. Posit (formerly RStudio) now supports Python as a first-class citizen in Posit Workbench, Connect, and Package Manager. Quarto documents can mix R and Python code chunks. Positron, their new IDE, targets both languages equally. This infrastructure investment signals that the industry's leading R platform sees the future as bilingual.
reticulate and rpy2. The reticulate R package enables calling Python from R with seamless data frame conversion. The rpy2 Python package does the reverse. These bridges allow teams to use the best tool for each subtask within a single pipeline—for example, using {admiral} for ADaM construction in R and then calling a Python ML model for a secondary endpoint.
Arrow and Parquet. Apache Arrow provides a language-agnostic in-memory columnar format with native bindings in both R (arrow package) and Python (pyarrow). Parquet files can be written by Python and read by R (or vice versa) with zero serialization overhead. This shared data layer is particularly relevant as the industry transitions from SAS transport (XPT) to modern formats.
Dataset-JSON. The CDISC Dataset-JSON v1.1 format is language-agnostic by design. Both R and Python can natively produce and consume JSON, making Dataset-JSON a natural convergence point that reduces the historical advantage SAS held through the XPT format. As FDA acceptance of Dataset-JSON expands, the choice of programming language becomes further decoupled from the submission format.
Python and R are not competitors in the clinical programming space—they are complementary tools with overlapping capabilities and distinct strengths. R's statistical heritage, pharmaverse ecosystem, and growing regulatory track record make it the more natural successor to SAS for traditional statistical programming tasks. Python's general-purpose power, ML ecosystem, and engineering integration make it the stronger choice for data pipelines, advanced analytics, and cross-functional collaboration.
For statistical programmers, the strategic investment is not choosing one language but developing working proficiency in both. The industry is converging on bilingual workflows where R handles statistical modeling and regulatory-facing outputs while Python handles data engineering and advanced analytics. The organizations that will navigate this transition most effectively are those that match the tool to the task rather than mandating a single language for all purposes.
The SAS-to-open-source transition is not a single migration—it is an expansion of the toolkit. Python and R, together, represent that expanded toolkit. The practitioner who understands both is positioned not just for today's submissions, but for the clinical data science workflows of the next decade.
© 2026 clinstandards.org. All rights reserved.
No comments yet. Be the first!